Go-ahead for doubling of the dose in Tripep’s alphaHGA study after evaluation of safety in the now completed first dose group.

In Tripep’s ongoing placebo controlled phase I/II clinical study on alphaHGA-treatment of HIV infected patients in Thailand the first dose group has now been completed. 12 patients were treated with active substance and 4 with placebo. The patients have received treatment three times daily for 4 weeks. Possible side effects have now been evaluated by a safety committee, which is independent of Tripep, before starting the treatment of the two new dose groups in which the daily dose is doubled and given two or three times a day, respectively. In the first dose group no serious side effects have been noted. The few side effects reported have been of mild and self-limiting nature. The code for which patients have received active drug or placebo has not been broken and will not be broken until the entire study of totally 48 patients has been completed. This is expected to happen in the end of the first quarter 2006. “It is with pleasure we can report that we now have passed the first threshold in the clinical development program of alphaHGA in humans. We can also state that the study in Thailand so far has been conducted in a very professional manner by the clinical investigators at Ramathibodi Hospital in Bangkok. Now, we are looking forward with eager excitement to receiving the results from all dose groups and whether alphaHGA will have an effect on the HIV-levels also in humans,” says Tripep’s CEO Jan Nilsson. For more information, please contact: Rolf L. Nordström, Chairman, Tripep AB Tel: +44 20 7839 8686, mobile phone: +44 7776 137 400 E-mail: rolf.l.nordstrom@btinternet.com Jan Nilsson, CEO, Tripep AB Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63 E-mail: jan.nilsson@tripep.se Anders Vahlne, Head of Research, Tripep AB Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28 E-mail: anders.vahlne@labmed.ki.se